Key points are not available for this paper at this time.
Background 0.001). The proportion of participants meeting the ADA target of A1C 7.0% increased from n=1 (0.6%) at baseline to n=91 (51.4%) at one year. Those meeting the HEDIS target of A1C 8.0% increased from 19.2% at baseline to 85.9% at one year. CGM outcomes (n=109) after near-continuous use included an increase in TIR of 9.9% ± 29.4 (p0.001) and a large increase in TITR (p0.001, Table). Conclusion: Self-guided use of CGM by primary care patients with T2D for one year was associated with clinically meaningful improvements in A1C and TIR. Disclosure T. Grace: Speaker's Bureau; Sanofi, Novo Nordisk, Eli Lilly and Company, Dexcom, Inc. Employee; Dexcom, Inc. J.E. Layne: Employee; Dexcom, Inc. Stock/Shareholder; Dexcom, Inc. Employee; Verily Life Sciences. C. Hicks: Employee; Dexcom, Inc. C.R. Green: Employee; Dexcom, Inc. T.C. Walker: Employee; Dexcom, Inc. Stock/Shareholder; Dexcom, Inc.
Grace et al. (Fri,) studied this question.